glp-1 agonists for diabetes Drug Savings: A Complete Guide How to Save on Ozempic, Wegovy, and More GLP-1/GIP Receptor Agonists and Diabetic

doi: 10.1210/jc.2011-2407

This includes trials of drug combinations such as Novo Nordisks CagriSema that combines semaglutide with investigational drug cagrilintide to improve efficacy

Last weeks JAMA had two articles on GLP-1 drugs that point to their promise for treatment of diseases beyond the conditions for which they are already approved by the FDA: obesity, diabetes, cardiovascular risk, sleep apnea and metabolic liver disease

Oxidative stress, a key mediator of cardiovascular damage in diabetes and obesity, is significantly attenuated by GLP-1 agonists through multiple mechanisms [32]

When ASCVD predominates: ASCVD is considered to predominate if a patient has established ASCVD or if they have indicators of high ASCVD risk

The half-life of these drugs varies widely (see table below) from two weeks with the extended-release form of exenatide (Bydureon Bcise), which is injected weekly, to thirteen hours for the daily injected liraglutide (Victoza, Saxenda)